원격 간질 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Tele-Epilepsy Market was valued at USD 408.1 million in 2023 and is projected to grow at a CAGR of 15.9% from 2024 to 2032. This growth is primarily driven by the rising prevalence of epilepsy and an increasing demand for remote management solutions.

Heightened awareness and acceptance of telehealth, along with supportive government policies and favorable reimbursement frameworks, are set to accelerate the adoption of tele-epilepsy services. Notably, the Centers for Medicare and Medicaid Services (CMS) highlighted a significant 64% surge in telehealth visits for chronic conditions, including epilepsy, over the last five years, underscoring the growing reliance on remote healthcare.

The expanding elderly demographic, more prone to epilepsy, combined with a general uptick in epilepsy cases, is poised to drive market growth as the demand for remote healthcare solutions intensifies. The World Health Organization (WHO) reported in 2023 that around 50 million people globally are affected by epilepsy, with a notable portion being elderly. This widespread prevalence accentuates the necessity for ongoing monitoring and management, underscoring the pivotal role of advanced tele-epilepsy technologies in ensuring effective care.

The overall industry is divided into component, epilepsy type, age group, end-user, and region.

The market, segmented by component, includes software, services, and hardware. Dominating the market, the software segment is projected to grow at a CAGR of 16.2% during the forecast period. Within the software category, there is a distinction between cloud-based and on-premises solutions. The software's market dominance stems from its crucial function in remote monitoring and epilepsy management, equipping stakeholders with essential tools for data collection and patient engagement. These software solutions facilitate real-time EEG monitoring, data analysis, and teleconsultations for ensuring continuous patient care, timely interventions, and tailored treatment plans that bolster the effectiveness of epilepsy management.

Segmented by epilepsy type, the tele-epilepsy market includes focal seizure, generalized seizure, and combined seizure categories. In 2023, the generalized seizure segment led the market with a 59.7% share, driven by the high prevalence and intricate management needs of these seizures. Given that generalized seizures impact both brain hemispheres simultaneously, they often necessitate continuous monitoring and regular treatment adjustments.

U.S. tele-epilepsy market was valued at USD 218.7 million in 2023 and is projected to soar to USD 795.5 million by the end of 2032. This robust growth is attributed to the high prevalence of epilepsy in the U.S., driving demand for advanced management solutions. The U.S. advantage lies in its established healthcare infrastructure and the widespread embrace of telehealth technologies, from remote diagnostics to teleconsultation platforms. Moreover, supportive government initiatives, favorable reimbursement policies, and relentless technological advancements further cement the U.S.'s dominant position in the tele-epilepsy market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of epilepsy
    • 3.2.1.2 Growing demand for remote monitoring services
    • 3.2.1.3 Technological advancement in telehealth services
    • 3.2.1.4 Rising awareness among patients and caregivers
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Data security and privacy concerns
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Software
  • 5.2.1 Cloud-based
  • 5.2.2 On-premises
• 5.3 Services
  • 5.3.1 Tele-consultation services
  • 5.3.2 Tele-monitoring and screening services
  • 5.3.3 Tele-education and training
  • 5.3.4 Other services
• 5.4 Hardware

Chapter 6 Market Estimates and Forecast, By Epilepsy Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Focal seizure
• 6.3 Generalized seizure
• 6.4 Combined seizure

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatrics
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Healthcare providers
  • 8.2.1 Hospitals and clinics
  • 8.2.2 Specialized epilepsy centers
  • 8.2.3 Homecare settings
• 8.3 Patients
• 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Bioserenity SAS
• 10.2 Ceribell, Inc.
• 10.3 CortiCare, Inc.
• 10.4 Epitel, Inc.
• 10.5 Empatica Inc.
• 10.6 MedaSync.
• 10.7 Medtronic plc
• 10.8 NeuroPace, Inc.
• 10.9 Ovation Healthcare
• 10.10 Real Time Tele-Epilepsy Consultants.
• 10.11 ScienceSoft USA Corporation
• 10.12 Seer Medical
• 10.13 Teladoc Health, Inc.
• 10.14 UCB S.A.
• 10.15 Vidyo, Inc.